Factors Contributing to the Preference of Korean Patients with Crohn’s Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
2
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Background/Aims: Two comparable anti-tumor necrosis factor (TNF) agents with different routes of administration (intravenous [iv] infliximab [IFX] vs subcutaneous [sc] adalimumab [ADA]) are available for patients with Crohn’s disease (CD) in Korea. This study aimed to identify the preferences of Korean CD patients for a specific anti-TNF agent and the factors contributing to the decision. Methods: A prospective survey was performed among anti-TNF-naive CD patients in 10 tertiary referral hospitals. A 16-item questionnaire addressed patient preferences and the factors contributing to the decision in favor of a particular anti-TNF agent. A logistic regression was conducted to assess predictive factors for ADA preference. Results: Overall, 189 patients (139 males; mean age, 32.47±11.71 years) completed the questionnaire. IFX and ADA were preferred by 63.5% (120/189) and 36.5% (69/189) of patients, respectively. The most influential reason for choosing IFX was ‘doctor’s presence’ (68.3%, 82/120), and ADA was “easy to use” (34.8%, 24/69). Amid various clinicodemographic data, having a >60-minute travel time to the hospital was a significant independent predictive factor for ADA preference. Conclusions: A large number of anti-TNF-naive Korean patients with CD preferred anti-TNFs with an iv route of administration. The reassuring effect of a doctor’s presence might be the main contributing factor for this decision.
Abstract
Background/Aims: Two comparable anti-tumor necrosis factor (TNF) agents with different routes of administration (intravenous [iv] infliximab [IFX] vs subcutaneous [sc] adalimumab [ADA]) are available for patients with Crohn’s disease (CD) in Korea. This study aimed to identify the preferences of Korean CD patients for a specific anti-TNF agent and the factors contributing to the decision. Methods: A prospective survey was performed among anti-TNF-naive CD patients in 10 tertiary referral hospitals. A 16-item questionnaire addressed patient preferences and the factors contributing to the decision in favor of a particular anti-TNF agent. A logistic regression was conducted to assess predictive factors for ADA preference. Results: Overall, 189 patients (139 males; mean age, 32.47±11.71 years) completed the questionnaire. IFX and ADA were preferred by 63.5% (120/189) and 36.5% (69/189) of patients, respectively. The most influential reason for choosing IFX was ‘doctor’s presence’ (68.3%, 82/120), and ADA was “easy to use” (34.8%, 24/69). Amid various clinicodemographic data, having a >60-minute travel time to the hospital was a significant independent predictive factor for ADA preference. Conclusions: A large number of anti-TNF-naive Korean patients with CD preferred anti-TNFs with an iv route of administration. The reassuring effect of a doctor’s presence might be the main contributing factor for this decision.
참고문헌 (32)
- Vermeire S, "Review article: altering the natural history of Crohn’s disease: evidence for and against current therapies", Aliment Pharmacol Ther, 25, pp.3~12 (2007)
- Reinecker HC, "Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease", Clin Exp Immunol, 94, pp.174~181 (1993)
- van Assche G, "Mucosal healing and anti TNFs in IBD", Curr Drug Targets, 11, pp.227~233 (2010)
- Chen-Wang Chang, "Safety and Efficacy of Adalimumab for Patients With Moderate to Severe Crohn’s Disease: The Taiwan Society of Inflammatory Bowel Disease (TSIBD) Study", Intestinal research, 12(4), pp.287~292 (2014), 대한장연구학회
- 김남희, "Long-Term Clinical Outcomes of Korean Patient With Crohn’s Disease Following Early Use of Infliximab", Intestinal research, 12(4), pp.281~286 (2014), 대한장연구학회
- Yang SK, "Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study", Inflamm Bowel Dis, 14, pp.542~549 (2008)
- Lee KM, "Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study", J Gastroenterol Hepatol, 28, pp.1829~1833 (2013)
- 예병덕, "크론병 치료 가이드라인", 대한소화기학회지, 59(2), pp.141~179 (2012), 대한소화기학회
- 최창환, "궤양성 대장염 치료 가이드라인", 대한소화기학회지, 59(2), pp.118~140 (2012), 대한소화기학회
- 이강문, "Crohn’s disease in Korea: past, present, and future", The Korean Journal of Internal Medicine, 29(5), pp.558~570 (2014), 대한내과학회[DOI]
- Rutgeerts P, "Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease", Gastroenterology, 117, pp.761~769 (1999)
- Hanauer SB, "Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial", Lancet, 359, pp.1541~1549 (2002)
- Hanauer SB, "Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease:the CLASSIC-I trial", Gastroenterology, 130, pp.323~333 (2006)
- Colombel JF, "Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial", Gastroenterology, 132, pp.52~65 (2007)
- Guadagnoli E, "Patient participation in decision-making", Soc Sci Med, 47, pp.329~339 (1998)
- Silliman RA, "Breast cancer care in older women: sources of information, social support, and emotional health outcomes", Cancer, 83, pp.706~711 (1998)
- van den Bemt BJ, "How can we improve adherence to therapy by patients with rheumatoid arthritis?", Clin Pract Rheumatol, 3, pp.681~ (2007)
- Baars JE, "Patients’preferences regarding shared decision-making in the treatment of inflammatory bowel disease: results from a patient-empowerment study", Digestion, 81, pp.113~119 (2010)
- Siegel CA, "Shared decision making in inflammatory bowel disease:helping patients understand the tradeoffs between treatment options", Gut, 61, pp.459~465 (2012)
- Vavricka SR, "Systematic assessment of factors influencing preferences of Crohn’s disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL)", Inflamm Bowel Dis, 18, pp.1523~1530 (2012)
- Chilton F, "Treatment choices, preferences and decisionmaking by patients with rheumatoid arthritis", Musculoskeletal Care, 6, pp.1~14 (2008)
- Williams EL, "Patient preferences in choosing anti-TNF therapies-R1", Rheumatology, 45, pp.1575~1576 (2006)
- Nisbett RE, "Culture and systems of thought: holistic versus analytic cognition", Psychol Rev, 108, pp.291~310 (2001)
- Talhelm T, "Large-scale psychological differences within China explained by rice versus wheat agriculture", Science, 344, pp.603~608 (2014)
- Constantinescu F, "Racial disparities in treatment preferences for rheumatoid arthritis", Med Care, 47, pp.350~355 (2009)
- Constantinescu F, "Understanding why rheumatoid arthritis patient treatment preferences differ by race", Arthritis Rheum, 61, pp.413~418 (2009)
- 예병덕, "크론병 진단 가이드라인", 대한소화기학회지, 53(3), pp.161~176 (2009), 대한소화기학회
- Kitayama S, "Independence and interdependence predict health and wellbeing:divergent patterns in the United States and Japan", Front Psychol, 1, pp.163~ (2010)
- Oyserman D, "Rethinking individualism and collectivism: evaluation of theoretical assumptions and meta-analyses", Psychol Bull, 128, pp.3~72 (2002)
- Scharl M, "Review: new anti-cytokines for IBD. What is in the pipeline?", Curr Drug Targets, 14, pp.1405~1420 (2013)
- Lobatón T, "Review article:anti-adhesion therapies for inflammatory bowel disease", Aliment Pharmacol Ther, 39, pp.579~594 (2014)
- Street RL Jr, "Patient participation in deciding breast cancer treatment and subsequent quality of life", Med Decis Making, 17, pp.298~306 (1997)